TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24577485
Drug: Dabigatran 150
Normalized name: dabigatran 150 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran 150 mg bid and Rivaroxaban
Study: 20818821
Drug: Bismuth pectin
Normalized name: bismuth / pectin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth pectin quadruple therapy (20 mg rabeprazole bid, 1000 mg amoxicillin bid, 100 mg bismuth pectin qid, and 500 mg levofloxacin qd)
Study: 20818821
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (20 mg omeprazole bid, 1000 mg amoxicillin bid for 5 d, followed by 20 mg omeprazole bid, 500 mg tinidazole bid, 500 mg clarithromycin bid for another 5 d)
Study: 20818821
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy (20 mg omeprazole bid, 1000 mg amoxicillin bid, 500 mg clarithromycin bid)
Study: 15193180
Drug: vax‐SPIRAL vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: vax‐SPIRAL vaccine
Study: 15193180
Drug: Heberbiovac‐HB (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heberbiovac‐HB (control vaccine)
Study: 9753212
Drug: Azithromycin (therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (therapeutic doses) with rifabutin 300 mg/day
Study: 9753212
Drug: Clarithromycin (therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (therapeutic doses) with rifabutin 300 mg/day
Study: 9753212
Drug: Rifabutin 300
Normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifabutin 300 mg/day alone
Study: 3364811
Drug: Etomidate (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate (0.3 and 0.15 mg.kg‐1 respectively)
Study: 3364811
Drug: Thiopentone (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone (3 and 1.5 mg.kg‐1 respectively)
Study: 25488056
Drug: Saccharomyces cerevisiae
Normalized name: Saccharomyces cerevisiae
DrugBank: Saccharomyces cerevisiae (DB10447)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saccharomyces cerevisiae (500 mg once daily for 8 weeks)
Study: 14697066
Drug: Infant orthopedic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infant orthopedic treatment (IO)
Study: 14697066
Drug: Non-infant orthopedic
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-infant orthopedic treatment (non-IO)
Study: 10667615
Drug: CCK‐4 (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCK‐4 (0.5 mg/60 min)
Study: 1969198
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg itraconazole daily for 3 to 6 months
Study: 1969198
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg itraconazole daily for 6 to 8 months
Study: 1969198
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg itraconazole daily for 6 months
Study: 1969198
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg itraconazole daily
Study: 24378762
Drug: Behavioral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral therapy (BT) (n = 55); goal setting, problem-solving, and stimulus control
Study: 23134211
Drug: linagliptin 5
Normalized name: linagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: linagliptin 5 mg/day
Study: 15047649
Drug: Low-intensity laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity laser therapy (LILT)
Study: 11496809
Drug: Enuresis alarm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enuresis alarm treatment
Study: 2557881
Drug: Doxorubicin 60‐75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 60‐75 mg m‐2 intravenously once every 3 weeks
Study: 2557881
Drug: Recombinant alpha
Normalized name: Recombinant alpha glucosidase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant alpha 2 interferon (rIFN) 9‐18 x 10(6) IU m‐2 intramuscularly daily
Study: 2557881
Drug: Recombinant alpha
Normalized name: Recombinant alpha glucosidase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant alpha 2 interferon (rIFN) 25‐50 x 10(6) IU m‐2 intramuscularly three times weekly
Study: 31046481
Drug: IL-23/p19 inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-23/p19 inhibitors
Study: 23993130
Drug: Ofloxacin 400mg
Normalized name: OFLOXACIN 400MG TAB
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ofloxacin 400mg twice daily plus Metronidazole 500mg twice daily
Study: 22232563
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of 1.25 mg bevacizumab
Study: 17326710
Drug: Hypoglycemia induced
Normalized name: Drugs for treatment of hypoglycemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycemia induced by insulin infusion to nadir levels of 2.2 mmol/l
Study: 12364470
Drug: High-dose GH
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose GH (0.05 mg/kg.d)
Study: 12364470
Drug: Low-dose GH
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose GH (0.025 mg/kg.d)
Study: 12364470
Drug: High-dose GH-IGFBP-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose GH-IGFBP-3 generation test
Study: 9845100
Drug: Continuous hyperfractionated
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous hyperfractionated accelerated radiation therapy with mitomycin C (V‐CHART + MMC)
Study: 9845100
Drug: Continuous hyperfractionated
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous hyperfractionated accelerated radiation therapy (V‐CHART)
Study: 7978438
Drug: Clonidine (transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (transdermal 0.2 mg/d for 72 h + oral 0.3 mg 60‐90 min before surgery)
Study: 17631296
Drug: Tesaglitazar (0.1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tesaglitazar (0.1, 0.25, 0.5, and 1mg) once daily for 12 weeks
Study: 16729760
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment + bioactive substances in formula CognoBlend (2 capsules twice a day for 5 weeks)
Study: 15314590
Drug: Subtenons lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subtenons lidocaine injection (1 ml of 2% lidocaine)
Study: 15314590
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no subtenons lidocaine injection)
Study: 9294492
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment at a daily subcutaneous dose of 0.2 or 0.3 IU/kg for 2 years
Study: 8322989
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of diamorphine added to 4 ml of 0.5% bupivacaine
Study: 8322989
Drug: 4 ml
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml of 0.5% bupivacaine alone
Study: 29652275
Drug: Ketofol infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketofol infusion (ketamine: propofol, 1mg: 3 mg in 20 ml syringe)
Study: 29652275
Drug: Dexmedetomidine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine infusion (200 μg in 20 ml normal saline)
Study: 22687642
Drug: Pioglitazone 15
Normalized name: pioglitazone 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 15 mg/day for two months (PIO 15)
Study: 22687642
Drug: Pioglitazone 15
Normalized name: pioglitazone 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 15 mg/day for one month followed by 30 mg/day for an additional one month (PIO 30)
Study: 10961590
Drug: Budesonide CIR
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide CIR 15 mg
Study: 10961590
Drug: Budesonide CIR
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide CIR 9 mg
Study: 9200284
Drug: Cisapride 10
Normalized name: cisapride 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 10 mg, four times daily for 4 weeks
Study: 3103572
Drug: 0.75 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg/kg of tissue plasminogen activator (rt‐PA)
Study: 31658051
Drug: Intravenous omega-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous omega-3 poly-unsaturated fatty acids (n-3 PUFAs)
Study: 22542530
Drug: Atorvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (10 mg/day) / Ezetimibe (10 mg/day)
Study: 20087195
Drug: Once-nightly dosing
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once-nightly dosing (didanosine plus lamivudine with efavirenz)
Study: 20087195
Drug: Twice-daily dosing
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily dosing (combivir with efavirenz)
Study: 20087195
Drug: Once-nightly dosing
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once-nightly dosing
Study: 18833174
Drug: Transcranial dynamic
Normalized name: water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial dynamic magnetic therapy (along with basic therapy)
Study: 9640146
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide at 20 vpm
Study: 9640146
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide at 1 vpm
Study: 9640146
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide at 40 vpm
Study: 9640146
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide at 10 vpm
Study: 7660402
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy in women
Study: 25700806
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate (FF) 400 mcg and umeclidinium (UMEC) 500 mcg administered in combination (FF/UMEC 100/125 mcg)
Study: 31434037
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate (FF) 100 mcg
Study: 25700806
Drug: Umeclidinium (UMEC)
Normalized name: Umeclidinium
DrugBank: Umeclidinium (DB09076)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Umeclidinium (UMEC) 125 mcg
Study: 8357774
Drug: Benazepril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril (10 or 20 mg once daily)
Study: 3900590
Drug: Verapamil 80
Normalized name: verapamil 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 80 mg every 8 hours for 5 days
Study: 24579804
Drug: Dorsal onlay
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorsal onlay buccal mucosa graft (BMG) urethroplasty
Study: 19558428
Drug: Fluconazole cream
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole cream 0.5%
Study: 19558428
Drug: Fluconazole cream
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole cream 1%
Study: 19558428
Drug: Flutrimazole cream
Normalized name: flutrimazole
DrugBank: Flutrimazole (DB13425)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutrimazole cream 1%
Study: 14722144
Drug: H pylori
Normalized name: Helicobacter pylori
Approvals — FDA: no, EMA: no, PMDA: no
Description: H pylori eradication treatment (2-week course of omeprazole 20 mg, amoxicillin and clavulanate potassium 750 mg, and metronidazole 400 mg, all twice daily, n = 817)
Study: 14722144
Drug: H pylori
Normalized name: Helicobacter pylori
Approvals — FDA: no, EMA: no, PMDA: no
Description: H pylori eradication treatment (n = 817)
Study: 9181649
Drug: Loracarbef (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loracarbef (200 mg twice daily for 10 days)
Study: 9181649
Drug: Phenoxymethylpenicillin (800/1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenoxymethylpenicillin (800/1000 mg twice daily for 10 days)
Study: 4077772
Drug: 5-nitroimidazole compounds
Normalized name: 2-methyl-5-nitroimidazole-1-ethanol
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-nitroimidazole compounds (including satranidazole, ronidazole, S75 0400 A)
Study: 4077772
Drug: Other antiprotozoal
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antiprotozoal drugs (berberine sulphate, paromomycin sulphate, erythromycin estolate, sulphasalazine)
Study: 25770814
Drug: Aprepitant plus
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprepitant plus ondansetron on day 1, followed by aprepitant on days 2 and 3 (125 mg for ages 12-17 years; 3.0 mg/kg up to 125 mg for ages 6 months to <12 years; 80 mg for ages 12-17 years; 2.0 mg/kg up to 80 mg for ages 6 months to <12 years)
Study: 21591943
Drug: Alemtuzumab (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alemtuzumab (30 mg, one dose)
Study: 21591943
Drug: Rabbit antithymocyte
Normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabbit antithymocyte globulin (6 mg/kg over 4 days)
Study: 21591943
Drug: Basiliximab (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basiliximab (40 mg over 4 days)
Study: 12565779
Drug: Plain aqueous
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain aqueous gel
Study: 10874260
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy for myocardial infarction
Study: 9114992
Drug: Cetirizine 5
Normalized name: cetirizine 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 5 mg once daily
Study: 30329030
Drug: Measles vaccination
Normalized name: Measles vaccine (live)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measles vaccination in the presence of maternal measles antibodies
Study: 29949429
Drug: Cabergoline (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline (3 mg/week)
Study: 29949429
Drug: Raloxifene (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (60 mg twice daily)
Study: 27114605
Drug: Cetuximab monotherapy
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab monotherapy (400 mg/m2 loading dose and then 250 mg/m2 once per week)
Study: 27114605
Drug: Cetuximab plus
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab plus irinotecan (cetuximab 400 mg/m2 loading dose and then 250 mg/m2 once per week with irinotecan 180 mg/m2 once every 2 weeks)
Study: 18026625
Drug: Group 1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1: Vaccine stored within the cold chain and administered in township hospitals
Study: 18026625
Drug: Group 2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2: Vaccine stored out of the cold chain in villages and administered by village-based health workers
Study: 18026625
Drug: Group 3:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3: Same strategy as group 2, but vaccine packaged in a prefilled injection device
Study: 16051334
Drug: Paclitaxel combined
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel combined with fixed doses of carboplatin
Study: 9700123
Drug: Antithrombin (AT)
Normalized name: antithrombin III
DrugBank: Antithrombin gamma (DB16094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombin (AT) therapy
Study: 7923999
Drug: Lactulose (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose (1 g/100 kcals to a maximum of 28 g/d)
Study: 2645313
Drug: Synthetic GnRH
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic GnRH (7.5, 25, 75, and 250 ng/kg) iv at 2-h intervals after long term pulsatile GnRH administration
Study: 2645313
Drug: Synthetic GnRH
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic GnRH (various doses)
Study: 21856044
Drug: Peripheral intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral intravenous access
Study: 28100482
Drug: Subtenon injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subtenon injection of 0.1 mL of 0.01% MMC
Study: 17032001
Drug: High-L spinach
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-L spinach ('Spinner')
Study: 17032001
Drug: Low-L spinach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-L spinach ('Springer')
Study: 15483415
Drug: Anti-TNF therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNF therapy (neutralizing antibody directed against tumor necrosis factor) at varying doses for 6, 24, or 48 hours
Study: 15483415
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no anti-TNF therapy)
Study: 9084461
Drug: rhPTH(1-84) at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhPTH(1-84) at doses 0.02 to 5.0 micrograms.kg-1
Study: 9084461
Drug: rhPTH(1-84) at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhPTH(1-84) at doses > 2.5 micrograms.kg-1
Study: 9084461
Drug: rhPTH(1-84) at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhPTH(1-84) at doses > or = 1.5 micrograms.kg-1
Study: 3278068
Drug: Naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 500 mg suppositories twice daily
Study: 3278068
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 1000 mg effervescent tablets three times daily
Study: 24427287
Drug: Thrombin-reactive phages
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombin-reactive phages selected using biotinylated anti-thrombin antibodies and streptavidin-coated magnetic beads.
Study: 17617557
Drug: 20 G
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 G Optiva i.v. plastic cannula
Study: 9698949
Drug: Single-injection spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-injection spinal anaesthesia (SA)
Study: 751811
Drug: Insight-oriented treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insight-oriented treatment
Study: 751811
Drug: Problem-Solving therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-Solving therapy
Study: 7034929
Drug: MTX 5
Normalized name: MTX
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX 5 g/m2
Study: 7034929
Drug: MTX 500
Normalized name: MTX
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX 500 mg/m2
Study: 7034929
Drug: MTX 50
Normalized name: MTX
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX 50 mg/m2
Study: 7034929
Drug: MTX (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX (all doses)
Study: 19938332
Drug: Oral functional
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral functional training
Study: 19938332
Drug: Tongue pressure
Normalized name: beef tongue preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongue pressure and oral diadochokinesis (pronouncing 'ka')
Study: 15351752
Drug: Routine influenza
Normalized name: INFLUENZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine influenza vaccination (injected or intranasal spray)
Study: 15351752
Drug: Injectable vaccine
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable vaccine for infants (6 months to 35 months)
Study: 10414674
Drug: Ketoprofen, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen, 100 mg, three times a day
Study: 10414674
Drug: Acetaminophen, 1
Normalized name: Acetaminophen, 120 mg/5 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen, 1 g, three times a day
Study: 8649915
Drug: 0.6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg/kg dexamethasone syrup
Study: 8649915
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg dexamethasone syrup
Study: 8649915
Drug: 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/kg dexamethasone syrup
Study: 2180259
Drug: Very low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low dose bromocriptine
Study: 2180259
Drug: Higher dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dosage regimen of bromocriptine
Study: 2180259
Drug: Maintenance dosage
Normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance dosage of bromocriptine (5 mg-15 mg daily)
Study: 25586468
Drug: Rindopepimut and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rindopepimut and standard adjuvant temozolomide chemotherapy
Study: 23533460
Drug: D&G herbal
Approvals — FDA: no, EMA: no, PMDA: no
Description: D&G herbal capsules 1 gm/day
Study: 23533460
Drug: D&G herbal
Approvals — FDA: no, EMA: no, PMDA: no
Description: D&G herbal capsules 2 gm/day
Study: 21942183
Drug: Medication (Glibenclamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (Glibenclamide 2.5‐7.5 mg/time, 1‐2 times/d for 12 weeks)
Study: 21942183
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between Acupuncture and Medication
Study: 19826060
Drug: dexlansoprazole MR
Normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dexlansoprazole MR 90 mg
Study: 19826060
Drug: dexlansoprazole MR
Normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dexlansoprazole MR 300 mg
Study: 7829780
Drug: MS-857 (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: MS-857 (15 mg, n = 10)